Akili Interactive, a US-based prescription digital medicine developer, has raised $55m in a series C funding round led by investment firm Temasek.
The funding round was also joined by Baillie Gifford, Amgen Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Fund and Brooklands Capital Strategies.
Akili focuses on the development of digital treatments for cognitive disorders delivered through video game experiences instead of a pill.
The company intends to use the funds to develop its prescription digital treatments pipeline through regulatory milestones and commercial launch.
It also plans to advance its existing product candidates designed for treating depression and multiple sclerosis (MS) into potential registration trials as well as expand its pipeline.
Akili Interactive co-founder and CEO Eddie Martucci said: “We are thrilled with the vote of confidence in the potential of our technology platform to redefine healthcare, and we’re excited about the progress we continue to make towards turning that vision into a reality for patients.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The company already completed a multi-centre, randomised, controlled pivotal study of its lead investigational candidate, AKL-T01, being developed for paediatric attention-deficit/hyperactivity disorder (ADHD) treatment.
Over the coming months, Akili expects to obtain results from another pilot randomised controlled trial (RCT) being conducted to assess its AKL-T02 product in high-functioning children with autism spectrum disorders (ASD).
Additionally, two separate clinical trials are underway to assess AKL-T03 for cognitive dysfunction treatment in adults suffering from depression, and MS, respectively.